A new oral medication to treat patients in the early stages of multiple sclerosis(多发性硬化) has shown considerable promise in two clinical trials, researchers announced on Wednesday.
The medication is on track to become just the third oral drug available to M.S. patients, and potentially the safest and most effective, experts said. The second oral drug, called Aubagio, was approved just last week.
The new trials, published online in The New England Journal of Medicine, found that the drug BG-12, developed by Biogen Idec, reduced relapsing M.S rates(旧病复发率)in patients by about 50 percent. The drug also obviously reduced the frequency of new brain damage , and slowed the progression of disease compared with a placebo(安慰剂).
In the two clinical trials, called Define and Confirm, patients were divided into two groups at random, taking 240 milligrams of BG-12 either twice or three times a day. Patients in a third group took a placebo. The combined results showed that the drug reduced the relapse rate by about 50 percent.
Taking BG-12 twice a day reduced the number of newly enlarging brain damages by 71 percent to 99 percent. The Define trial found a statistically significant 38 percent reduction in the progression to disability. The most frequent side effects were a temporary flushing(脸红)and warm feeling and other symptoms including nausea, diarrhea, cramping and vomiting. Though both types of side effects were common, they tended to reduce after the first few weeks of use and were tolerated by most patients.
【(3年高考2年模拟)2016届高三英语二轮突破 阅读理解特训39(含解析)】相关文章:
★ 重庆市2014高考英语阅读理解一轮(精品)训练题(12)附答案
★ 2017高考四川省广安市英语阅读理解一轮系列训练:6(含解析)
★ 2017届高考英语二轮复习书面表达限时测验:5(含解析)
★ 2017届高考英语二轮复习大题冲关秘籍阅读理解七选五:解题策略(含解析)
★ 【优化方案】2017届高考英语二轮复习全国卷Ⅱ题型重组训练:第20组(含解析)
★ 【优化方案】2017届高考英语二轮复习全国卷Ⅱ题型重组训练:第16组(含解析)
最新
2017-04-24
2017-04-24
2017-04-24
2017-04-24
2017-04-21
2017-04-21